Schwab Charles Investment Management Inc. boosted its holdings in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 59.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 374,825 shares of the medical research company’s stock after purchasing an additional 139,895 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.59% of PRA Health Sciences worth $28,551,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 160 shares during the last quarter. Carroll Financial Associates Inc. raised its stake in shares of PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 790 shares during the last quarter. Comerica Bank bought a new position in shares of PRA Health Sciences during the third quarter valued at about $214,000. Trustmark National Bank Trust Department bought a new position in shares of PRA Health Sciences during the second quarter valued at about $225,000. Finally, Aperio Group LLC bought a new position in shares of PRA Health Sciences during the second quarter valued at about $233,000. 98.49% of the stock is owned by institutional investors and hedge funds.

Several brokerages have recently commented on PRAH. Barclays began coverage on shares of PRA Health Sciences in a research note on Monday. They set an “overweight” rating and a $94.00 price objective for the company. Mizuho set a $87.00 price objective on shares of PRA Health Sciences and gave the company a “buy” rating in a research note on Friday, December 1st. SunTrust Banks reaffirmed a “buy” rating and set a $101.00 price objective on shares of PRA Health Sciences in a research note on Friday, October 27th. Credit Suisse Group reissued an “outperform” rating and issued a $90.00 price target (up from $84.00) on shares of PRA Health Sciences in a research note on Monday, October 16th. Finally, KeyCorp reissued a “buy” rating and issued a $93.00 price target (up from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $89.50.

PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at $83.75 on Tuesday. PRA Health Sciences, Inc. has a one year low of $53.47 and a one year high of $84.38. The stock has a market cap of $5,241.31, a PE ratio of 30.41, a P/E/G ratio of 1.43 and a beta of 0.40. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to the consensus estimate of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. PRA Health Sciences’s revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 earnings per share. analysts anticipate that PRA Health Sciences, Inc. will post 3.2 EPS for the current year.

In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.10% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/12/schwab-charles-investment-management-inc-acquires-139895-shares-of-pra-health-sciences-inc-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.